At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Statin Polyp Prevention Trial in Patients With Resected Colon Cancer
In Brief
A Phase 3 clinical trial evaluating rosuvastatin and placebo for Colorectal Cancer and Precancerous Condition. Terminated early, enrolled 406 participants across 587 sites in 2 countries.
Signals
Detailed Summary
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery. PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.